Markus Raderer
#149,550
Most Influential Person Now
Researcher
Markus Raderer's AcademicInfluence.com Rankings
Markus Raderercomputer-science Degrees
Computer Science
#7760
World Rank
#8166
Historical Rank
Database
#4814
World Rank
#5000
Historical Rank
Download Badge
Computer Science
Markus Raderer's Degrees
- PhD Computer Science University of Vienna
- Masters Computer Science University of Vienna
- Bachelors Computer Science University of Vienna
Similar Degrees You Can Earn
Why Is Markus Raderer Influential?
(Suggest an Edit or Addition)Markus Raderer's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study (2016) (864)
- Lanreotide in metastatic enteropancreatic neuroendocrine tumors. (2014) (661)
- T(14;18)(q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma. (2003) (469)
- Variable frequencies of MALT lymphoma-associated genetic aberrations in MALT lymphomas of different sites (2004) (368)
- T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma (2005) (360)
- Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. (2003) (352)
- EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT (2011) (310)
- Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma (2006) (252)
- Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. (1994) (246)
- Inhibition of metastases by anticoagulants. (1999) (238)
- Involvement of P-glycoprotein in the transmembrane transport of interleukin-2 (IL-2), IL-4, and interferon-gamma in normal human T lymphocytes. (1996) (234)
- Clinical trials of agents that reverse multidrug resistance. A literature review (1993) (224)
- Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET. (2004) (211)
- Primary follicular lymphoma of the duodenum is a distinct mucosal/submucosal variant of follicular lymphoma: a retrospective study of 63 cases. (2011) (182)
- Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. (2003) (181)
- Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study (2016) (179)
- Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. (2001) (178)
- Palliative chemotherapy for advanced gastric cancer. (2004) (175)
- Association between Helicobacter pylori Infection and Pancreatic Cancer (1997) (174)
- Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. (2003) (173)
- Assessment of disease dissemination in gastric compared with extragastric mucosa-associated lymphoid tissue lymphoma using extensive staging: a single-center experience. (2006) (171)
- High Relapse Rate in Patients with MALT Lymphoma Warrants Lifelong Follow-up (2005) (170)
- Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. (2004) (168)
- Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type. (1999) (168)
- Most patients with minimal histological residuals of gastric MALT lymphoma after successful eradication of Helicobacter pylori can be managed safely by a watch and wait strategy: experience from a large international series (2007) (167)
- Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality (2015) (163)
- The impact of hemoglobin levels on fatigue and quality of life in cancer patients. (2002) (159)
- Importance of extensive staging in patients with mucosa-associated lymphoid tissue (MALT)-type lymphoma (2000) (157)
- Clinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa‐associated lymphoid tissue (MALT lymphoma) (2016) (153)
- High incidence of t(11;18)(q21;q21) in Helicobacter pylori-negative gastric MALT lymphoma. (2003) (141)
- The role of chemotherapy and radiation in the management of biliary cancer: a review of the literature. (1998) (137)
- Two Consecutive Phase II Studies of 5-Fluorouracil/Leucovorin/Mitomycin C and of Gemcitabine in Patients with Advanced Biliary Cancer (1999) (137)
- Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a phase II study. (2002) (133)
- Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2020) (131)
- The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing? (2002) (131)
- A MALT lymphoma prognostic index. (2017) (127)
- Templated nucleotide addition and immunoglobulin JH-gene utilization in t(11;14) junctions: implications for the mechanism of translocation and the origin of mantle cell lymphoma. (2001) (120)
- Mucosa-Associated Lymphoid Tissue Lymphoma: Novel Translocations Including Rearrangements of ODZ2, JMJD2C, and CNN3 (2008) (119)
- 18F-Fluorodeoxyglucose Positron Emission Tomography (18F-FDG-PET) for Staging and Follow-Up of Marginal Zone B-Cell Lymphoma (2003) (119)
- Rituximab for Treatment of Advanced Extranodal Marginal Zone B Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue Lymphoma (2003) (119)
- 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading. (2006) (117)
- High levels of eosinophil cationic protein in wheezing infants predict the development of asthma. (1997) (117)
- Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010) (116)
- Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma (2003) (116)
- Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation (2002) (108)
- Treatment of pruritus in chronic liver disease with the 5‐hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo‐controlled, double‐blind cross‐over trial (1998) (107)
- Esophageal cancer: a critical evaluation of systemic second-line therapy. (2011) (106)
- Successful antibiotic treatment of Helicobacter pylori negative gastric mucosa associated lymphoid tissue lymphomas (2005) (105)
- Ondansetron for pruritus due to cholestasis. (1994) (104)
- Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response (2012) (99)
- Evaluation of Diffusion-Weighted MRI for Pretherapeutic Assessment and Staging of Lymphoma: Results of a Prospective Study in 140 Patients (2014) (98)
- MALT lymphoma in patients with autoimmune diseases: a comparative analysis of characteristics and clinical course (2007) (97)
- PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL). (2014) (97)
- Differential expression of NF-κB target genes in MALT lymphoma with and without chromosome translocation: insights into molecular mechanism (2010) (93)
- Experience with indium-111 and yttrium-90-labeled somatostatin analogs. (2002) (92)
- Antibiotic treatment is not effective in patients infected with Helicobacter pylori suffering from extragastric MALT lymphoma. (2006) (91)
- Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer. (1999) (91)
- Autoimmune thrombocytopenia in non-Hodgkin’s lymphomas (2008) (89)
- Indium-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumor patients. (1998) (84)
- Vasoactive intestinal peptide receptor scintigraphy. (1995) (82)
- Antibiotic therapy in nongastrointestinal MALT lymphoma: a review of the literature. (2013) (81)
- Evaluation of Diffusion-Weighted Magnetic Resonance Imaging for Follow-up and Treatment Response Assessment of Lymphoma: Results of an 18F-FDG-PET/CT–Controlled Prospective Study in 64 Patients (2015) (80)
- A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma) (2013) (80)
- Regression of colonic low grade B cell lymphoma of the mucosa associated lymphoid tissue type after eradication ofHelicobacter pylori (2000) (79)
- 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) for assessment of enteropathy-type T cell lymphoma (2003) (79)
- 18F-Fluoro-deoxy-glucose positron emission tomography in lymphoma of mucosa-associated lymphoid tissue: histology makes the difference. (2006) (77)
- Thromboembolic events during treatment with thalidomide. (2002) (77)
- Nonsurgical management of malignant thymoma (1999) (74)
- Treatment of hepatocellular cancer with the long acting somatostatin analog lanreotide in vitro and in vivo. (2000) (74)
- Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma (2011) (74)
- Monoclonal Immunoglobulin Production Is a Frequent Event in Patients with Mucosa-Associated Lymphoid Tissue Lymphoma (2004) (73)
- PET/MRI versus PET/CT in oncology: a prospective single-center study of 330 examinations focusing on implications for patient management and cost considerations (2019) (73)
- Extranodal marginal zone B‐cell lymphoma of mucosa‐associated lymphoid tissue of the head and neck area (2003) (72)
- High efficacy of concomitant treatment of undifferentiated (anaplastic) thyroid cancer with radiation and docetaxel. (2010) (72)
- Palliative chemotherapy for recurrent and metastatic esophageal cancer. (2007) (70)
- Frequency of Chromosomal Aberrations Involving MALT1 in Mucosa-Associated Lymphoid Tissue Lymphoma in Patients with Sjögren’s Syndrome (2004) (70)
- 'Blind' antibiotic treatment targeting Chlamydia is not effective in patients with MALT lymphoma of the ocular adnexa. (2006) (68)
- A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours. (2016) (68)
- Subcutaneous administration of amifostine: a promising therapeutic option in patients with oxaliplatin-related peripheral sensitive neuropathy. (2001) (67)
- Dissemination patterns in non-gastric MALT lymphoma (2008) (66)
- Decrease of duration and symptoms in chemotherapy-induced oral mucositis by topical GM-CSF: results of a prospective randomised trial. (2001) (66)
- Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomis (2018) (66)
- Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with mitoxantrone, chlorambucil and prednisone (MCP). (2003) (65)
- A phase II study of bortezomib in patients with MALT lymphoma (2009) (64)
- Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx). (2018) (64)
- Rituximab monotherapy for primary cutaneous B-cell lymphoma: response and follow-up in 16 patients. (2009) (60)
- Impaired response of gastric MALT-lymphoma to Helicobacter pylori eradication in patients with autoimmune disease. (2001) (60)
- Does MALT lymphoma of the lung require immediate treatment? An analysis of 11 untreated cases with long-term follow-up. (2007) (60)
- Value of peptide receptor scintigraphy using (123)I-vasoactive intestinal peptide and (111)In-DTPA-D-Phe1-octreotide in 194 carcinoid patients: Vienna University Experience, 1993 to 1998. (2000) (59)
- Overexpression of G protein‐coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma (2012) (59)
- Activity of Rituximab plus Cyclophosphamide, Doxorubicin/Mitoxantrone, Vincristine and Prednisone in Patients with Relapsed MALT Lymphoma (2007) (57)
- Chemotherapy for management of localised high-grade gastric B-cell lymphoma: how much is necessary? (2002) (57)
- Oxaliplatin plus raltitrexed in patients with advanced colorectal carcinoma (2001) (55)
- Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) for treatment of early-stage gastric diffuse large B-cell lymphoma. (2004) (55)
- Cancer polyarthritis resembling rheumatoid arthritis as a first sign of hidden neoplasms. Report of two cases and review of the literature. (2001) (55)
- Comparative somatostatin receptor scintigraphy using in-111-DOTA-lanreotide and in-111-DOTA-Tyr3-octreotide versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated radionuclide therapy. (2001) (54)
- Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. (2017) (54)
- Endoscopic ultrasound in the follow up and response assessment of patients with primary gastric lymphoma (2002) (53)
- A phase II trial of biweekly high dose gemcitabine for patients with metastatic pancreatic adenocarcinoma (2000) (53)
- CD5 Expression in a Lymphoma of the Mucosa-Associated Lymphoid Tissue (MALT)-Type as a Marker for Early Dissemination and Aggressive Clinical Behaviour (2001) (52)
- Response to treatment with yttrium 90-DOTA-lanreotide of a patient with metastatic gastrinoma. (1998) (52)
- Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma) (2021) (51)
- New trends in peptide receptor radioligands. (2001) (51)
- Translocation t(11;18)(q21;q21) Is Not Predictive of Response to Chemotherapy with 2CdA in Patients with Gastric MALT Lymphoma (2004) (51)
- Prolonged clinical remission in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type treated with cladribine: 6 year follow-up of a phase II trial. (2006) (50)
- Chemotherapy for the treatment of patients with primary high grade gastric B‐cell lymphoma of modified Ann Arbor stages IE and IIE (2000) (49)
- Helicobacter pylori eradication as exclusive treatment for limited-stage gastric diffuse large B-cell lymphoma: results of a multicenter phase 2 trial. (2012) (49)
- Chronic autoimmune thyroiditis (Hashimoto's thyroiditis) in patients with MALT lymphoma. (2008) (49)
- Phase II study of oxaliplatin for treatment of patients with mucosa-associated lymphoid tissue lymphoma. (2005) (48)
- Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factor. (2002) (47)
- 123I-vasoactive intestinal peptide (VIP) receptor scanning: update of imaging results in patients with adenocarcinomas and endocrine tumors of the gastrointestinal tract. (1996) (46)
- Chlamydia psittaci Infection in nongastrointestinal extranodal MALT lymphomas and their precursor lesions. (2011) (46)
- Antibiotic treatment as sole management of Helicobacter pylori-negative gastric MALT lymphoma: a single center experience with prolonged follow-up (2015) (45)
- SARS-CoV-2 Testing in Patients With Cancer Treated at a Tertiary Care Hospital During the COVID-19 Pandemic. (2020) (44)
- High-dose clarithromycin is an active monotherapy for patients with relapsed/refractory extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT): the HD-K phase II trial. (2015) (44)
- Novel GPR34 and CCR6 mutation and distinct genetic profiles in MALT lymphomas of different sites (2018) (43)
- Randomized multicenter phase II trial of oxaliplatin plus irinotecan versus raltitrexed as first-line treatment in advanced colorectal cancer. (2002) (43)
- Influenza vaccination perception and coverage among patients with malignant disease. (2015) (42)
- A retrospective international study on primary extranodal marginal zone lymphoma of the lung (BALT lymphoma) on behalf of International Extranodal Lymphoma Study Group (IELSG) (2016) (42)
- Effective combination chemotherapy with paclitaxel and cisplatin with or without human granulocyte colony-stimulating factor and/or erythropoietin in patients with advanced gastric cancer (2002) (42)
- Intermittent weekly high-dose capecitabine in combination with oxaliplatin: a phase I/II study in first-line treatment of patients with advanced colorectal cancer. (2002) (42)
- Whole-Body 68Ga-DOTANOC PET/MRI Versus 68Ga-DOTANOC PET/CT in Patients With Neuroendocrine Tumors (2017) (42)
- Chemotherapy with cyclophosphamide, doxorubicin, etoposide, vincristine and prednisone (CHOEP) is not effective in patients with enteropathy-type intestinal T-cell lymphoma. (2004) (42)
- A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma. (2017) (42)
- Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy. (2001) (40)
- Cytotoxic activity of camptothecin and paclitaxel in newly established continuous human medullary thyroid carcinoma cell lines. (2004) (40)
- Gadoxetate-enhanced versus diffusion-weighted MRI for fused Ga-68-DOTANOC PET/MRI in patients with neuroendocrine tumours of the upper abdomen (2013) (40)
- Treatment of Small Intestinal Neuroendocrine Tumors: Is an Extended Multimodal Approach Justified? (2002) (40)
- Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma (1999) (40)
- Humoral Immune Response in Hematooncological Patients and Health Care Workers Who Received SARS-CoV-2 Vaccinations. (2021) (39)
- Treatment of Advanced Hepatocellular Carcinoma with Biweekly High-Dose Gemcitabine (2001) (38)
- 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma (2016) (37)
- Spartalizumab in metastatic, well/poorly-differentiated neuroendocrine neoplasms. (2021) (37)
- Bevacizumab is active in malignant effusion. (2006) (37)
- 18F-fluorodeoxyglucose (FDG)-PET features of focal nodular hyperplasia (FNH) of the liver. (2000) (37)
- Positron emission tomography with [18F] 2-fluoro-D-2- deoxyglucose in primary cutaneous T-cell lymphomas. (2004) (36)
- Postoperative chemotherapy for gastric cancer. (2006) (36)
- Somatostatin-receptor scintigraphy for staging and follow-up of patients with extraintestinal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT)-type (2001) (36)
- FAS (CD95) mutations are rare in gastric MALT lymphoma but occur more frequently in primary gastric diffuse large B-cell lymphoma. (2004) (36)
- Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib (2016) (35)
- Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure l-isomer of leucovorin for the treatment of advanced colorectal cancer: a randomized phase III study. (1997) (35)
- Treatment of advanced colorectal cancer with 5-fluorouracil and interferon-alpha: an overview of clinical trials. (1995) (35)
- Iodine-123-vasoactive intestinal peptide receptor scanning in patients with pancreatic cancer. (1998) (35)
- Effects of chemotherapeutic agents on expression of somatostatin receptors in pancreatic tumor cells. (2001) (35)
- [68Ga]Ga-Pentixafor PET/MRI for CXCR4 Imaging of Chronic Lymphocytic Leukemia: Preliminary Results (2018) (35)
- Clinical activity of everolimus in relapsed/refractory marginal zone B‐cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (2014) (35)
- Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a phase II study by the Arbeitsgemeinschaft Medikamentöse Tumortherapie (2013) (34)
- Rituximab plus bendamustine is active in pretreated patients with extragastric marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma) (2014) (34)
- Tissue polypeptide-specific antigen (TPS) in monitoring palliative treatment response of patients with gastrointestinal tumours. (1995) (34)
- Clinical Features, Treatment and Outcome of Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma of the Ocular Adnexa: Single Center Experience of 60 Patients (2014) (34)
- Prognostic relevance of hypoxia inducible factor‐1α expression in patients with melanoma (2009) (33)
- Response of a nonmalignant pleural effusion to bevacizumab. (2005) (33)
- Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary (2017) (33)
- Chemoimmunotherapy for Mucosa-Associated Lymphoid Tissue-Type Lymphoma: A Review of the Literature. (2015) (32)
- Treatment of patients with advanced nonsmall cell lung carcinoma using docetaxel and gemcitabine plus granulocyte‐colony stimulating factor (2000) (32)
- Retrospective comparison of the effectiveness of various treatment modalities of extragastric MALT lymphoma: a single-center analysis (2014) (32)
- Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders (2021) (32)
- 123I-labelled vasoactive intestinal peptide receptor scintigraphy in patients with colorectal cancer. (1998) (32)
- Prospective non-invasive evaluation of CXCR4 expression for the diagnosis of MALT lymphoma using [68Ga]Ga-Pentixafor-PET/MRI (2019) (31)
- Chromosomal imbalances in primary and metastatic pancreatic carcinoma as detected by interphase cytogenetics: basic findings and clinical aspects. (1998) (31)
- 111In-DOTA-lanreotide scintigraphy in patients with tumors of the lung. (2001) (31)
- Therapy of gastric mucosa-associated lymphoid tissue lymphoma (2007) (31)
- High expression of Dicer reveals a negative prognostic influence in certain subtypes of primary cutaneous T cell lymphomas. (2011) (30)
- 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) does not visualize follicular lymphoma of the duodenum (2004) (30)
- Third dose of SARS-CoV-2 vaccination in hemato-oncological patients and health care workers: immune responses and adverse events – a retrospective cohort study (2022) (29)
- Pathology and clinical course of MALT lymphoma with plasmacytic differentiation. (2007) (29)
- Randomized Phase II Study of Irinotecan Plus Mitomycin C vs. Oxaliplatin Plus Mitomycin C in Patients with Advanced Fluoropyrimidine/Leucovorin-Pretreated Colorectal Cancer (2002) (29)
- New radiopharmaceuticals for receptor scintigraphy and radionuclide therapy. (2000) (28)
- Oxaliplatin-Induced Fever and Release of IL-6 (2000) (28)
- Treatment of advanced colorectal cancer with doxorubicin combined with two potential multidrug-resistance-reversing agents: high-dose oral tamoxifen and dexverapamil (2005) (28)
- Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509) (2021) (28)
- Gemcitabine for the Treatment of Advanced Biliary Tract Carcinomas: Evaluation of Two Different Dose Regimens (1999) (27)
- Transformation of MALT lymphoma to pure plasma cell histology following treatment with the anti-CD20 antibody rituximab (2005) (27)
- Aerosolised iloprost improves pulmonary haemodynamics in patients with primary pulmonary hypertension receiving continuous epoprostenol treatment (2001) (27)
- Second-Line Treatment of Advanced Gastric Cancer with Oxaliplatin plus Raltitrexed (2003) (26)
- Assessment of the role of hepatitis C, Helicobacter pylori and autoimmunity in MALT lymphoma of the ocular adnexa in 45 Austrian patients (2008) (26)
- IGH and MALT 1 is a frequent chromosomal aberration in MALT lymphoma (2003) (26)
- Pre- and postoperative treatment modalities for esophageal squamous cell carcinoma. (2012) (25)
- Reinduction therapy with the same cytostatic regimen in patients with advanced colorectal cancer. (1998) (25)
- In vitro and in vivo studies of three radiolabelled somatostatin analogues:123I-Octreotide (OCT),123I-Tyr-3-OCT and111In-TIRA-d-Phe-1-OCT (1996) (25)
- Differential somatostatin and CXCR4 chemokine receptor expression in MALT-type lymphoma of gastric and extragastric origin (2016) (24)
- Extranodal lymphoma of MALT-type: perspective at the beginning of the 21st century (2001) (24)
- Serum levels of vasoactive intestinal peptide (VIP) in patients with adenocarcinomas of the gastrointestinal tract. (2001) (24)
- Influence of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone on serologic parameters and clinical course in lymphoma patients with autoimmune diseases. (2006) (24)
- MALT lymphoma associated genetic aberrations occur at different frequencies in primary and secondary intestinal MALT lymphomas (2006) (23)
- Effective Combination Chemotherapy with Bimonthly Docetaxel and Cisplatin with or without Hematopoietic Growth Factor Support in Patients with Advanced Gastroesophageal Cancer (2003) (23)
- Sustained Response to Vemurafenib in a BRAFV600E-Mutated Anaplastic Thyroid Carcinoma Patient. (2016) (22)
- Successful Symptomatic Management of a Patient with Ménétrier’s Disease with Long-Term Antibiotic Treatment (1999) (22)
- Resveratrol pretreatment desensitizes AHTO-7 human osteoblasts to growth stimulation in response to carcinoma cell supernatants. (1999) (22)
- Complete regression of primary gastric plasmacytoma following Helicobacter pylori eradication (2004) (22)
- Efficacy of lenvatinib in patients with advanced pancreatic (panNETs) and gastrointestinal (giNETs) grade 1/2 (G1/G2) neuroendocrine tumors: Results of the international phase II TALENT trial (GETNE 1509). (2018) (22)
- Significant association between TNFAIP3 inactivation and biased immunoglobulin heavy chain variable region 4‐34 usage in mucosa‐associated lymphoid tissue lymphoma (2017) (21)
- Early progression of disease predicts shorter survival in MALT lymphoma patients receiving systemic treatment. (2020) (21)
- The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of Vienna (2016) (21)
- Clinicopathological aspects of mucosa‐associated lymphoid tissue (MALT) lymphoma of the parotid gland: A retrospective single‐center analysis of 28 cases (2011) (21)
- 90Y-ibritumomab tiuxetan (Zevalin) in heavily pretreated patients with mucosa associated lymphoid tissue lymphoma (2011) (21)
- Serum troponin T levels in adults undergoing anthracycline therapy. (1997) (21)
- Technetium-99m-galactosyl-neoglycoalbumin combined with iodine-123-Tyr-(A14)-insulin visualizes human hepatocellular carcinomas. (1995) (21)
- Postchemotherapy rheumatism following adjuvant therapy for ovarian cancer. (1994) (21)
- Final results of the TALENT trial (GETNE1509): a prospective multicohort phase II study of lenvatinib in patients (pts) with G1/G2 advanced pancreatic (panNETs) and gastrointestinal (giNETs) neuroendocrine tumors (NETs). (2019) (21)
- Cell Surface Membrane Antigen Phenotype of Human Gastrointestinal Mast Cells (2005) (20)
- Comparison of iodine-123-vasoactive intestinal peptide receptor scintigraphy and indium-111-CYT-103 immunoscintigraphy. (1996) (20)
- Effective treatment of advanced breast cancer with vinorelbine, 5-fluorouracil and l-leucovorin plus human granulocyte colony-stimulating factor. (1998) (20)
- Different Response to the Long-Acting Somatostatin Analogues Lanreotide and Octreotide in a Patient with a Malignant Carcinoid (2001) (20)
- Clarithromycin as a “repurposing drug” against MALT lymphoma (2018) (20)
- Enhanced SARS-CoV-2 breakthrough infections in patients with hematologic and solid cancers due to Omicron (2022) (20)
- Plasmacytic differentiation in MALT lymphomas following treatment with rituximab (2012) (19)
- Nonpegylated liposomal doxorubicin is highly active in patients with B and T/NK cell lymphomas with cardiac comorbidity or higher age (2010) (19)
- Mesenchymal stem cells in patients with chronic myelogenous leukaemia or bi-phenotypic Ph+ acute leukaemia are not related to the leukaemic clone. (2007) (19)
- Acute pulmonary toxicity associated with high-dose vinorelbine and mitomycin C. (1996) (19)
- Resection of Hilar Cholangiocarcinomas: Pivotal Prognostic Factors and Impact of Tumor Sclerosis (2003) (19)
- Effective treatment of primary plasma cell leukemia with thalidomide and dexamethasone - a case report. (2004) (19)
- Impact of Single or Combined Genomic Alterations of TP53, MYC, and BCL2 on Survival of Patients With Diffuse Large B-Cell Lymphomas (2015) (19)
- Role of chemotherapy in gastric MALT lymphoma, diffuse large B-cell lymphoma and other lymphomas. (2010) (18)
- Progression-free survival (PFS) with lanreotide autogel/depot (LAN) in enteropancreatic NETs patients: The CLARINET extension study. (2014) (18)
- TNFAIP3 abnormalities in MALT lymphoma with autoimmunity (2011) (18)
- Coincidence of Crohn’s Disease and a High-Risk Gastrointestinal Stromal Tumor of the Terminal Ileum (1999) (18)
- Topical granulocyte-macrophage colony-stimulating factor in patients with cancer and impaired wound healing. (1997) (18)
- Real-World Data for Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer (RELEVANT): A Retrospective Multicentric Analysis of Clinical Practice in Austria (2020) (18)
- Does Delayed-Time-Point Imaging Improve 18F-FDG-PET in Patients With MALT Lymphoma? (2016) (18)
- Somatostatin receptor expression in primary gastric versus nongastric extranodal B-cell lymphoma of mucosa-associated lymphoid tissue type. (1999) (18)
- Increased resting heart rate and prognosis in treatment‐naïve unselected cancer patients: results from a prospective observational study (2020) (17)
- The role of nuclear medicine in the diagnosis of cancer of unknown origin. (2004) (17)
- Absence of efficacy of thalidomide monotherapy in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma). (2009) (17)
- Primary Gastric Mantle Cell Lymphoma in a Patient with Long Standing History of Crohn's Disease (2004) (17)
- Correlation between glycolytic activity on [18F]‐FDG‐PET and cell density on diffusion‐weighted MRI in lymphoma at staging (2018) (17)
- Second line chemotherapy in patients with enteropathy-associated T cell lymphoma: a retrospective single center analysis (2011) (17)
- Expression of somatostatin receptor 2A in medullary thyroid carcinoma is associated with lymph node metastasis (2016) (17)
- Can Interim 18F-FDG PET or Diffusion-Weighted MRI Predict End-of-Treatment Outcome in FDG-Avid MALT Lymphoma After Rituximab-Based Therapy?: A Preliminary Study in 15 Patients (2016) (17)
- Early Cancer of the Stomach Arising after Successful Treatment of Gastric MALT Lymphoma in Patients with Autoimmune Disease (2003) (17)
- Treatment of mucosa associated lymphoid tissue lymphoma with a long‐term once‐weekly regimen of oral azithromycin: Results from the phase II MALT—A trial (2018) (16)
- Rituximab plus dose-reduced cyclophosphamide, mitoxantrone, vincristine, and prednisolone are effective in elderly patients with diffuse large B-cell lymphoma of the thyroid. (2010) (16)
- Treatment of advanced pancreatic cancer with the long-acting somatostatin analogue lanreotide: in vitro and in vivo results (1999) (16)
- Final progression-free survival (PFS) analyses for lanreotide autogel/depot 120 mg in metastatic enteropancreatic neuroendocrine tumors (NETs): The CLARINET extension study. (2017) (16)
- Distinction between hepatic focal nodular hyperplasia and malignant liver lesions using technetium-99m-galactosyl-neoglycoalbumin. (1997) (16)
- Assessment of the prognostic indices IPI and FLIPI in patients with mucosa-associated lymphoid tissue lymphoma. (2010) (16)
- Phase II study of docetaxel in combination with oxaliplatin in patients with metastatic or locally advanced esophagogastric cancer previously untreated with chemotherapy for advanced disease: results of the Central European Cooperative Oncology Group Study ESGAS.1.2.001 (2008) (16)
- The circulating form of neprilysin is not a general biomarker for overall survival in treatment-naïve cancer patients (2019) (16)
- Serum interleukin-6 levels in patients with gastric MALT lymphoma compared to gastric and pancreatic cancer. (2006) (16)
- Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy. (2001) (16)
- Effective radiochemotherapy with cisplatin and etoposide for the management of patients with locally inoperable and metastatic esophageal carcinoma (1996) (16)
- Mosaicism due to myeloid lineage restricted loss of heterozygosity as cause of spontaneous Rh phenotype splitting. (2007) (16)
- Amonafide as first-line chemotherapy for metastatic breast cancer. (1994) (15)
- Ultra-early response assessment in lymphoma treatment: [18F]FDG PET/MR captures changes in glucose metabolism and cell density within the first 72 hours of treatment (2018) (15)
- Delayed Efficacy After Treatment With Lenalidomide or Thalidomide in Patients With Mucosa-Associated Lymphoid Tissue Lymphoma. (2016) (15)
- CXCR4 PET imaging of mantle cell lymphoma using [68Ga]Pentixafor: comparison with [18F]FDG-PET (2021) (15)
- Evidence of Therapeutic Efficacy of CCNU in Recurrent Choroid Plexus Papilloma (2000) (15)
- Bone Marrow Involvement in Malignant Lymphoma: Evaluation of Quantitative PET and MRI Biomarkers. (2017) (14)
- Successful treatment of an advanced hepatocellular carcinoma with the long-acting somatostatin analog lanreotide (1999) (14)
- Effective Treatment of Indolent Non-Hodgkin’s Lymphomas with Mitoxantrone, Chlorambucil and Prednisone (2005) (14)
- Ondansetron for diarrhea associated with neuroendocrine tumors. (2013) (14)
- Mucosa-Associated LymphoidTissue Lymphoma : Novel Translocations Including Rearrangements of ODZ 2 , JMJD 2 C , and CNN 3 (2008) (14)
- Absence of Therapeutic Efficacy of the Somatostatin Analogue Lanreotide in Advanced Primary Hepatic Cholangiocellular Cancer and Adenocarcinoma of the Gallbladder Despite In Vivo SomatostatinReceptor Expression (2002) (14)
- The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) in daily practice: A real-life feasibility analysis at the Medical University Vienna. (2017) (14)
- Immunomodulatory treatment for mucosa‐associated lymphoid tissue lymphoma (MALT lymphoma) (2020) (13)
- Anal pruritus after cancer chemotherapy with gemcitabine. (1999) (13)
- Fatal liver failure after the administration of raltitrexed for cancer chemotherapy (2000) (13)
- Oral Ondansetron Offers Effective Antidiarrheal Activity for Carcinoid Syndrome Refractory to Somatostatin Analogs. (2018) (13)
- Treatment of advanced pancreatic cancer with epirubicin, 5-fluorouracil and 1-leucovorin: a phase II study. (1997) (13)
- Effective treatment of advanced breast cancer with vinorelbine, mitomycin C plus human granulocyte colony-stimulating factor. (1996) (13)
- How I treat neuroendocrine tumours (2020) (12)
- Phase II study of second-line oxaliplatin, irinotecan and mitomycin C in patients with advanced or metastatic colorectal cancer (2000) (12)
- Significant association between TNFAIP3 inactivation and biased IGHV4-34 usage in MALT lymphoma (2017) (12)
- Primary MALT-lymphoma of the liver: multimodality imaging. (2003) (12)
- Phase I/II trial of dexverapamil, epirubicin, and granulocyte‐macrophage–colony stimulating factor in patients with advanced pancreatic adenocarcinoma (1995) (12)
- Thyroid MALT lymphoma: self-harm to gain potential T-cell help (2021) (12)
- Pre-Therapeutic Total Lesion Glycolysis on [18F]FDG-PET Enables Prognostication of 2-Year Progression-Free Survival in MALT Lymphoma Patients Treated with CD20-Antibody-Based Immunotherapy (2019) (12)
- t(11;14)(q23;q32) involving IGH and DDX6 in nodal marginal zone lymphoma (2013) (12)
- Results of the extended analysis for cancer treatment (EXACT) trial: a prospective translational study evaluating individualized treatment regimens in oncology (2019) (12)
- Management of adrenocortical carcinoma: are we making progress? (2021) (12)
- Immunohistochemical expression of cereblon and MUM1 as potential predictive markers of response to lenalidomide in extranodal marginal zone B‐cell lymphoma of the mucosa‐associated lymphoid tissue (MALT lymphoma) (2018) (12)
- Improved Quality of Life in Patients Treated with Peptide Radionuclides (2011) (12)
- Autologous stem-cell transplantation in progressing amyloidosis is associated with severe transplant-related toxicity (2006) (12)
- Management of Gastric Mucosa-Associated Lymphoid Tissue Lymphoma (2014) (12)
- Vasoactive intestinal peptide and somatostatin receptor scintigraphy for differential diagnosis of hepatic carcinoid metastasis. (1997) (12)
- Subcutaneous dissemination pattern in extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue lymphoma (2012) (12)
- Phase II study of D-verapamil and doxorubicin in patients with metastatic colorectal cancer. (1993) (11)
- Irinotecan-related cholinergic syndrome induced by coadministration of oxaliplatin. (1998) (11)
- The impact of COVID‐19 on cancer care of outpatients with low socioeconomic status (2022) (11)
- Cutaneous recall phenomenon at the site of previous doxorubicin extravasation after second-line chemotherapy. (2007) (11)
- CXCR4 PET/MRI for follow-up of gastric mucosa–associated lymphoid tissue lymphoma after first-line Helicobacter pylori eradication (2021) (11)
- Final Results of a Multicenter Phase II Trial Assessing the Activity and Efficacy of Helicobacter Pylori-Eradicating Antibiotic Therapy As Exclusive Treatment for Patients with Stage I-II1 Diffuse Large B-Cell Lymphoma of the Stomach (the HGL-1 Trial) (2011) (11)
- Complete remission of chronic plaque psoriasis and gastric marginal zone B-cell lymphoma of MALT type after treatment with 2-chlorodeoxyadenosine (2002) (11)
- A pilot phase II study of ofatumumab monotherapy for extranodal marginal zone B‐cell lymphoma of the mucosa‐associated lymphoid tissue (MALT) lymphoma (2018) (11)
- Expression of human somatostatin receptor subtype 3 in pancreatic cancer in vitro and in vivo. (1998) (11)
- 111In-DOTA-dPhe1-Tyr3-octreotide, 111In-DOTA-lanreotide and 67Ga citrate scintigraphy for visualisation of extranodal marginal zone B-cell lymphoma of the MALT type: a comparative study (2003) (11)
- Comparison of Spiral-Computed Tomography with Water-Filling of the Stomach and Endosonography for Gastric Lymphoma of Mucosa-Associated Lymphoid Tissue-Type (2002) (11)
- Proceedings of the International Cancer Imaging Society (ICIS) 16th Annual Teaching Course (2016) (10)
- Somatostatin receptor scintigraphy with 111In-DOTA-lanreotide and 111In-DOTA-Tyr3-octreotide in patients with stage IV melanoma: in-vitro and in-vivo results (2005) (10)
- Prolonged follow‐up on lenalidomide‐based treatment for mucosa‐associated lymphoid tissue lymphoma (MALT lymphoma)—Real‐world data from the Medical University of Vienna (2019) (10)
- Treatment of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue with fludarabine: effect on tumor microenvironment (2011) (10)
- Prolonged response to a single androgen suppression phase in a subpopulation of prostate cancer patients. (2000) (10)
- 5LBA Everolimus in advanced nonfunctional neuroendocrine tumors (NET) of lung or gastrointestinal (GI) origin: Efficacy and safety results from the placebo-controlled, double-blind, multicenter, Phase 3 RADIANT-4 study (2015) (10)
- Primary mucosa-associated lymphoid tissue (MALT) lymphoma of the liver: clinical, molecular, and microbiological aspects (2012) (10)
- "MAURITIUS": tumour dose in patients with advanced carcinoma. (1999) (9)
- Case 2: myocardial metastases from a carcinoid tumor. (2000) (9)
- Transformed mucosa‐associated lymphoid tissue lymphomas: A single institution retrospective study including polymerase chain reaction‐based clonality analysis (2019) (9)
- Clarithromycin Leading to Complete Remission in the First-Line Treatment of Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma. (2015) (9)
- Recent Developments in Nongastric Mucosa-Associated Lymphoid Tissue Lymphoma (2011) (9)
- Rituximab, Ara-C, Dexamethasone and Oxaliplatin Is Safe and Active in Heavily Pretreated Patients with Diffuse Large B-Cell Lymphoma (2006) (9)
- Gender Aspects in Extranodal Marginal Zone B-Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue: Does Sex Matter? (2016) (8)
- Genetic Characterization and Clinical Features of Helicobacter pylori Negative Gastric Mucosa-Associated Lymphoid Tissue Lymphoma (2021) (8)
- Prevalence of clarithromycin-resistant Helicobacter pylori strains in gastric mucosa-associated lymphoid tissue lymphoma patients (2016) (8)
- Everolimus (EVE) in advanced, nonfunctional, well-differentiated neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin: second interim overall survival (OS) results from the RADIANT-4 Study. (2016) (8)
- Subclinical involvement of the liver is associated with prognosis in treatment naïve cancer patients (2017) (8)
- Marked Activity of Bortezomib, Rituximab, and Dexamethason in Relapsed and Refractory Mantle Cell Lymphoma. (2006) (8)
- 5-methyltetrahydrofolate for biochemical modulation of fluorouracil (FU) in patients with advanced colorectal cancer: a randomized phase I-II study of two different FU administration schedules. (1998) (8)
- Beta-2 microglobulin as a diagnostic parameter in non-Hodgkin lymphoma: a comparative study with FDG-PET. (2013) (8)
- GDF‐15 in solid vs non‐solid treatment‐naïve malignancies (2019) (8)
- New developments in extracutaneous lymphomas. (2000) (8)
- Gastrointestinal Involvement in Patients with Mantle Cell Lymphoma: A Single Center Experience of Eighty-Five Patients (2019) (8)
- How I treat MALT lymphoma: ‘a subjective interpretation of the gospel according to Isaacson….’ (2020) (8)
- EHA evaluation of the ESMO—Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies (2020) (8)
- Phase I/II trial of dexverapamil, epirubicin and granulocyte/macrophage-colony-stimulating factor in patients with advanced pancreatic adenocarcinoma. (1995) (7)
- Subclinical involvement of the liver is associated with prognosis in treatment naïve cancer patients. (2017) (7)
- 1096O Lanreotide autogel/depot (LAN) in patients with advanced bronchopulmonary (BP) neuroendocrine tumors (NETs): Results from the phase III SPINET study (2021) (7)
- Acute tumor pain in patients with head and neck cancer treated with vinorelbine. (1996) (7)
- Metachronous gastric MALT lymphoma and early gastric cancer. (2006) (7)
- Cutaneous paraneoplastic disorders in stomach cancer: Collaboration between oncologically active dermatologists and clinical oncologists. (2016) (7)
- Concomitant occurrence of MALT lymphoma and multiple myeloma (2004) (7)
- Interim analysis of a real-world precision medicine platform for molecular profiling of metastatic or advanced cancers: MONDTI (2019) (7)
- Evaluation of [18F]-FDG-Based Hybrid Imaging Combinations for Assessment of Bone Marrow Involvement in Lymphoma at Initial Staging (2016) (7)
- Routine application of the proton-pump inhibitor pantoprazole in patients with gastric lymphoma undergoing chemotherapy (2005) (6)
- Effects of lanreotide autogel/depot (LAN) in pancreatic neuroendocrine tumors (pNETs): A subgroup analysis from the CLARINET study. (2015) (6)
- Reverse Transcription-PCR for t(11;18)(q21;q21) Staging and Monitoring in Mucosa-Associated Lymphoid Tissue Lymphoma (2006) (6)
- Prognostic value of T-cell receptor γ rearrangement in peripheral blood or bone marrow of patients with peripheral T-cell lymphomas (2008) (6)
- Very good partial response in a patient with MALT-lymphoma of the lung after treatment with low-dose thalidomide (2005) (6)
- Detection of gastric MALT lymphoma spreading to the small bowel by enteroscopy. (2011) (6)
- Efficacy and safety of everolimus in advanced, progressive, nonfunctional neuroendocrine tumors (NET) of the gastrointestinal (GI) tract and unknown primary: A subgroup analysis of the phase III RADIANT-4 trial. (2016) (6)
- Somatostatin receptor scintigraphy in primary cutaneous T‐ and B‐cell lymphomas (2010) (6)
- Bilateral facial nerve palsy as first indication of relapsing hairy cell leukemia after 36 years (2004) (6)
- Early progression of disease predicts shorter survival in patients with mucosa-associated lymphoid tissue lymphoma receiving systemic treatment (2020) (6)
- Analysis of 10 Adrenocortical Carcinoma Patients in the Cohort of the Precision Medicine Platform MONDTI (2018) (6)
- A phase I/II trial of epirubicin and high dose tamoxifen as a potential modulator of multidrug resistance in advanced hepatocellular carcinoma. (1996) (6)
- Gastric MALT lymphoma (2009) (6)
- Depth of Remission Following First-Line Treatment Is an Independent Prognostic Marker for Progression-Free Survival in Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma (2020) (6)
- Durable remissions after rituximab plus thalidomide for relapsed/refractory mantle cell lymphoma. (2004) (6)
- Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia (2021) (6)
- Lanreotide depot/autogel (LAN) in patients with neuroendocrine tumors (NETs) aged 65 years: Subgroup analyses from the CLARINET study. (2015) (6)
- Imaging of cutaneous recurrence of gastric cancer with F-18 FDG positron emission tomography. (2002) (6)
- Occurrence of a pulmonary carcinoid following allogeneic stem cell transplantation for chronic myelogenous leukemia: a case report (2003) (6)
- Monoclonal gammmopathy (MG) in extranodal marginal zone lymphoma (ENMZL) (2005) (6)
- Phase II trial of high-dose gemcitabine in patients with metastatic pancreatic adenocarcinoma (1999) (6)
- Effective treatment of a peripheral T-cell lymphoma/lymphoepitheloid cell variant (Lennert's lymphoma) refractory to chemotherapy with the CD-52 antibody alemtuzumab (2005) (6)
- Effects of lanreotide autogel/depot (LAN) in patients with neuroendocrine tumors (NETs) age 65 or younger versus older than age 65: Subgroup analyses from the CLARINET study. (2015) (5)
- Progression-free survival (PFS) and subgroups analyses of lenvatinib in patients (pts) with G1/G2 advanced pancreatic (panNETs) and gastrointestinal (giNETs) neuroendocrine tumors (NETs): Updated results from the phase II TALENT trial (GETNE 1509). (2019) (5)
- Baseline demographics of the randomized, placebo-controlled, double-blind, phase III RADIANT-4 study of everolimus in nonfunctional gastrointestinal (GI) or lung neuroendocrine tumors (NET). (2015) (5)
- Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors (2019) (5)
- Lanreotide depot/autogel (LAN) in midgut neuroendocrine tumors (NETs): A subgroup analysis from the CLARINET study. (2015) (5)
- Modulation of CD99/MIC2 expression of human AHTO-7 osteoblasts by carcinoma cell line-conditioned media. (2001) (5)
- Long‐term safety and activity of cladribine in patients with extranodal B‐cell marginal zone lymphoma of the mucosa‐associated lymphoid tissue (MALT) lymphoma (2017) (5)
- Acquired C1 esterase inhibitor deficiency in lymphomas: prevalence, symptoms, and response to treatment (2016) (5)
- A pilot study of confocal laser endomicroscopy for diagnosing gastrointestinal mucosa-associated lymphoid tissue (MALT) lymphoma (2016) (5)
- DWI-MRI vs CT in gastric MALT lymphoma-preliminary results in 19 patients. (2018) (5)
- Neuroendocrine Carcinomas Arising in Solid-Organ Transplant Recipients: Rare but Aggressive Malignancies (2009) (5)
- Marked activity of bortezomib, rituximab, and dexamethasone (BORID) in heavily pretreated patients with mantle cell lymphoma. (2006) (5)
- The European Society for Medical Oncology 'Magnitude of Clinical Benefit Scale' field-tested in infrequent tumour entities: an extended analysis of its feasibility at the Medical University of Vienna (2017) (5)
- Evaluation of Diffusion-weighted Magnetic Resonance Imaging for Pre-therapeutic Assessment and Staging of Lymphoma : Results of a Prospective Study in 140 Patients (2014) (5)
- Impact of COVID‐19 lockdown on routine oncology versus emergency care at a high volume cancer centre (2021) (5)
- Phase II study of docetaxel in combination with oxaliplatin in patients with metastatic or locally advanced esophagogastric cancer previously untreated with chemotherapy for advanced disease. Results of the CECOG-Study ESGAS.1.2.001 (2007) (5)
- RECIL Versus Lugano for Treatment Response Assessment in FDG-Avid Non-Hodgkin Lymphomas: A Head-to-Head Comparison in 54 Patients (2019) (5)
- Targeted Therapy Recommendations for Therapy Refractory Solid Tumors—Data from the Real-World Precision Medicine Platform MONDTI (2020) (5)
- Beta-2-microglobulin levels in patients with extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type: a retrospective analysis. (2001) (5)
- A Phase l/ll Study of Quinidine, a Potential Multidrug Resistance-Reversing Agent, in Combination with Pirarubicin in Patients with Advanced Refractory Breast Cancer (1993) (5)
- How I treat medullary thyroid cancer (2021) (5)
- Inflammation-Based Scores as a Common Tool for Prognostic Assessment in Heart Failure or Cancer (2021) (5)
- Uptake of indium-111-labeled human polyclonal immunoglobulin G in pancreatic cancer: in vivo and in vitro studies. (2002) (5)
- Diffusion-Weighted MRI for Lymphoma Staging—Response (2015) (5)
- Everolimus for Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Gastrointestinal (GI) Tract: Efficacy and Safety From a RADIANT-4 Subgroup Analysis. (2016) (5)
- Lanreotide depot/autogel (LAN) in intestinal and pancreatic neuroendocrine tumors (NETs) according to body mass index (BMI): Subgroup analyses from the CLARINET study. (2015) (4)
- ABO blood group type and risk of venous thromboembolism in patients with cancer (2022) (4)
- [Neoadjuvant therapy for resectable esophageal cancer]. (2005) (4)
- Treatment of advanced gastric cancer with oral etoposide, leucovorin and tegafur: experience with an oral modification of the etoposide, leucovorin and 5-fluorouracil (ELF) regimen. (1998) (4)
- First Line Systemic Treatment for MALT Lymphoma—Do We Still Need Chemotherapy? Real World Data from the Medical University Vienna (2020) (4)
- SMALL INTESTINE 18 F-fluoro-deoxy-glucose positron emission tomography ( 18 F-FDG-PET ) for assessment of enteropathy-type T cell lymphoma (2003) (4)
- The multiple faces of marginal zone lymphomas (2017) (4)
- Successful Clarithromycin Monotherapy in a Patient with Primary Follicular Lymphoma of the Duodenum (2018) (4)
- Infection with multidrug-resistant Campylobacter coli mimicking recurrence of carcinoid syndrome: a case report of a neuroendocrine tumor patient with repeated diarrhea (2016) (4)
- The cancer survival index—A prognostic score integrating psychosocial and biological factors in patients diagnosed with cancer or haematologic malignancies (2022) (4)
- Rituximab, Ara-C, dexamethasone and oxaliplatin (R-ADOx) is effective for treatment of elderly patients with relapsed mantle cell lymphoma (2013) (4)
- A phase II study of the PI3K inhibitor copanlisib in combination with the anti-CD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: treatment rationale and protocol design of the COUP-1 trial (2021) (4)
- Mitomycin C, Vinorelbine, Carboplatin plus Granulocyte-Macrophage Colony-Stimulating Factor for Treatment of Advanced Non-Small Cell Lung Carcinoma (1998) (4)
- [Acceptance of and satisfaction with medical information provided to cancer patients]. (2001) (4)
- Bortezomib, Rituximab, and Dexamethason (BORID) as Salvage Treatment in Relapsed/Refractory Mantle Cell Lymphoma: Sustained Disease Control in Patients Achieving a Complete Remission. (2007) (4)
- Potential Pathogenetic Role of Achromobacter (Alcaligenes) Xylosoxidans in Primary Extranodal Marginal Zone Lymphoma of the Lung (BALT-Lymphoma): Update of the Results of a Retrospective Analysis on Behalf of IELSG (2011) (3)
- Is there a reliable size cut-off for splenic involvement in lymphoma? A [18F]FDG-PET controlled study (2019) (3)
- Second-Line Treatment of Advanced Colorectal Cancer with a Biweekly Oxaliplatin plus Irinotecan Combination Regimen (2002) (3)
- Chapter 6 – Colorectal Cancer (2018) (3)
- Prognostic factors for progression-free survival (PFS) in CLARINET study of lanreotide depot/autogel (LAN) vs placebo (PBO) in neuroendocrine tumors (NETs). (2015) (3)
- Chapter 3 – Breast Cancer (2018) (3)
- Cytogenetic analysis and fluorescence in situ hybridization in a case of IgD multiple myeloma. (1998) (3)
- Azithromycin concentrations during long-term regimen, a pilot study in patients with MALT lymphoma (2021) (3)
- Malignancy in slow motion: diagnosis of biochemically apparent, but otherwise occult persistent disease 21 years after resection of a carcinoid tumour of the terminal ileum. (2001) (3)
- 1143PPH II STUDY OF BEZ235 IN PATIENTS WITH ADVANCED PANCREATIC NEUROENDOCRINE TUMORS (PNET) AFTER MTOR INHIBITOR THERAPY FAILURE: STAGE I INTERIM RESULTS. (2014) (3)
- Treatment of localized primary gastric lymphoma. (2006) (3)
- 2331 Prognostic value of neutrophil/lymphocyte ratio in intestinal and pancreatic neuroendocrine tumors: exploratory analysis of data from the CLARINET trial of lanreotide depot/autogel (2015) (3)
- The potential evasion of immune surveillance in mucosa associated lymphoid tissue lymphoma by DcR2-mediated up-regulation of nuclear factor-κB (2015) (3)
- Running in the family: MALT lymphoma and autoimmune disease in mother and daughter. (2012) (3)
- Sex-differences in [68Ga]Ga-DOTANOC biodistribution. (2019) (3)
- Gender-Specific Aspects in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation: A Single-Center Experience (2017) (3)
- Concomitant occurrence of MALT lymphoma and multiple myeloma (2004) (3)
- t(3;14)(P14.1;Q32) Involving IGH and FOXP1 Is a Recurrent Chromosomal Aberration in MALT Lymphoma. (2004) (3)
- Experience with clarithromycin as antineoplastic therapy for extranodal marginal zone B‐cell lymphoma of the mucosa associated lymphoid tissue (MALT‐lymphoma) outside of clinical trials: Real‐world data from the University of Vienna (2020) (3)
- Long-term Therapeutic Success of Intravenous Rituximab in 26 Patients with Indolent Primary Cutaneous B-cell Lymphoma (2021) (3)
- Latent structure and measurement invariance of the Hospital Anxiety and Depression Scale in cancer outpatients (2022) (3)
- Gastroenteropancreatic Neuroendocrine Neoplasms (2018) (3)
- Helicobacter pylori and pancreatic cancer. A working hypothesis from epidemiological studies. (2003) (3)
- 2374 Multivariate analysis of progression-free survival in the CLARINET study of lanreotide Autogel/Depot vs placebo identifies prognostic factors in neuroendocrine tumours (2015) (3)
- Marginal Zone Lymphomas. (2020) (2)
- 1136PDQUALITY OF LIFE (QOL) WITH LANREOTIDE AUTOGEL (LAN) VS. PLACEBO IN PATIENTS WITH ENTEROPANCREATIC NEUROENDOCRINE TUMOURS (EP-NETS): RESULTS FROM THE CLARINET PHASE III STUDY. (2014) (2)
- Prevalence of anxiety and depression in people with different types of cancer or haematologic malignancies: a cross-sectional study (2022) (2)
- Re: Vinorelbine-induced pancreatitis: a case report. (1998) (2)
- EARLY PROGRESSION OF DISEASE (POD24) PREDICTS SHORTER SURVIVAL IN MALT LYMPHOMA PATIENTS RECEIVING SYSTEMIC TREATMENT (2019) (2)
- 451PFinal analysis of time to subsequent disease progression/death in patients with metastatic enteropancreatic neuroendocrine tumours progressing under placebo and switched to lanreotide autogel/depot 120mg in the CLARINET open-label extension (2017) (2)
- Final overall survival results of frontline bortezomib plus rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) vs R-CHOP in transplantation-ineligible patients (pts) with newly diagnosed mantle-cell lymphoma (MCL): A randomized, open-label, phase III (LYM-3002) study. (2018) (2)
- Retrospective Comparison of the Effectiveness of Various Treatment Modalities of Extragastric MALT Lymphoma: A single center analysis (2015) (2)
- CLARITHROMYCIN AS a “REPURPOSING DRUG” AGAINST LYMPHOMAS: SAFETY AND EFFICACY PROFILES IN 55 PATIENTS WITH EXTRANODAL MARGINAL ZONE LYMPHOMA (EMZL) (2017) (2)
- Stomach cancer and myositis ossificans-like lesions. (2011) (2)
- Radiation doses deriving from patients undergoing 111In-DTPA-d-Phe-1-octreotide scintigraphy (1997) (2)
- Treatment of Advanced Gastric Cancer with Oral Idarubicin, Leucovorin, and Tegafur (1999) (2)
- REGRESSION OF COLONICLOW GRADE B CELL LYMPHOMA OF THE MUCOSA ASSOCIATEDLYRNPHOID TISSUE TYPE AFTER ERADICATION OF HELICOBACTUPYHTRI (2000) (2)
- SARS-CoV-2 screening in cancer outpatients during the second wave of the COVID-19 pandemic (2021) (2)
- Malignant B‐cell Lymphoma, WHO Classification and the Respective 18F‐fluoro‐deoxy‐glucose Positron Emission Tomography Results (2006) (2)
- Safety and efficacy of everolimus in advanced nonfunctional Neuroendocrine Tumors (NET) of lung or Gastrointestinal (GI) origin: findings of the randomized, placebo-controlled, double-blind, multicenter, phase 3 RADIANT-4 study (2016) (2)
- Relative risk of adverse events with lanreotide depot/autogel (LAN) vs. placebo (PBO) in patients with intestinal and pancreatic neuroendocrine tumors (NETs). (2015) (2)
- Imaging Inflammation in Atherosclerosis with CXCR4-Directed [68Ga]PentixaFor PET/MRI—Compared with [18F]FDG PET/MRI (2022) (2)
- Successful retreatment with 3-week rituximab-bendamustine with high-dose dexamethasone in patients with relapsed/refractory mantle cell lymphoma (2018) (1)
- 99 P - Treatment of advanced breast cancer with vinorelbine (VLB), fluorouracil (FU), l-leucovorin (LLV) and human granulocyte colony-stimulating factor (GCSF) (1996) (1)
- Two-Monthly Rituximab Infusions Maintain Target Concentrations: Pharmacokinetic Data of the AGMT-NHL9 Maintenance Study in Patients with Follicular Lymphoma in Complete or Partial Remission. (2008) (1)
- Eribulin in Patients with Liposarcoma and Leiomyosarcoma: A Retrospective Single-Center Experience (2022) (1)
- [Treatment of patients with radioiodine refractory, differentiated thyroid carcinoma. A Consensus Statement]. (2015) (1)
- Lack of correlation between blood group and HER-2 status in adenocarcinomas of the upper gastrointestinal tract. (2013) (1)
- Erratum to: Differential somatostatin and CXCR4 chemokine receptor expression in MALT-type lymphoma of gastric and extragastric origin (2016) (1)
- What you always wanted to know about gastric MALT-lymphoma: a focus on recent developments (2021) (1)
- Second complete remission of Helicobacter pylori negative gastric MALT lymphoma following antibiotic treatment (2007) (1)
- Promising Activity of Bortezomib, Rituximab, and Dexamethason (BORID) in Patients with Relapsed Mantle Cell Lymphoma. (2005) (1)
- Adolescents and Young Adults (AYAs) With Initially Localized and Metastatic Bone Sarcomas: A Retrospective Single Center Analysis of Side Effect Management (2021) (1)
- Tolerance of the Novel Chemosensitizer Dexverapamil in Combination with Anthracycline Chemotherapy: a Prospective Toxicity Analysis in Advanced Gastrointestinal Cancer (1995) (1)
- Lack of severe cardiovascular side effects with dexverapamil (DEX), a novel chemosensitizer, in combination with anthracycline chemotherapy for patients with advanced gastrointestinal malignancies: 143 (1994) (1)
- Thirteen-year analyses of medical oncology outpatient day clinic data: a changing field (2020) (1)
- 1. Vasoactive intestinal peptide (VIP) receptor imaging versus TAG-72 imaging in patients with adenocarcinomas (1994) (1)
- Underlying autoimmune diseases are not aggravated during treatment with lenalidomide in patients with mucosa-associated lymphoid tissue lymphoma (2015) (1)
- How can we assess and measure prognosis for MALT lymphoma? A review of current findings and strategies (2021) (1)
- Positron emission tomography/magnetic resonance imaging (PET/MRI) vs. gastroscopy: Can it improve detection of extranodal marginal zone lymphomas of the stomach following H. pylori treatment? (2022) (1)
- The combination of 5-fluorouracil, leukovorin, etoposide, and cisplatin (FLEP) in patients with metastatic esophageal cancer. A single-institution experience. (2008) (1)
- Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial (2020) (1)
- Spontaneous Erections in a Patient with Erectile Dysfunction after Palliative Chemotherapy for Non-Small Cell Lung Cancer (2001) (1)
- 2370 Relative risk analysis of safety profile of lanreotide autogel/depot vs. placebo in patients with pancreatic and intestinal neuroendocrine tumours (2015) (1)
- Combined lanreotide autogel and temozolomide therapy in progressive neuroendocrine tumours: the SONNET study (2016) (1)
- Multimodality treatment of gastric cancer (2002) (1)
- The NET G3 enigma: dealing with a “new” entity (2022) (1)
- Comparative in vitro and in vivo studies with four radiolabelled somatostatin analogues in patients with endocrine tumours (1995) (0)
- Locally advanced gastric cancer treated with neoadjuvant chemotherapy: Epirubicin, oxaliplatin, and capecitabine (EOX). (2011) (0)
- DEPTH OF REMISSION FOLLOWING FIRST LINE HP‐ERADICATION IS AN INDEPENDENT PROGNOSTIC FACTOR IN GASTRIC MALT LYMPHOMA (2019) (0)
- OS03.7.A Clinical characteristics, treatment and long-term outcome of patients with brain metastases from thyroid cancer - an analysis of the Vienna Brain Metastasis Registry (2022) (0)
- [Determination of therapy management in rectal carcinoma by staging with 18-FDG-PET]. (2001) (0)
- Phase I/II trial of dexverapamil, epirubicin and granulocyte/macrophage-colony-stimulating factor in patients with advanced pancreatic adenocarcinoma (1995) (0)
- Bestimmung des Therapiemanagements beim Rectumcarcinom durch Staging mittels 18-FDG-PET (2001) (0)
- Neoadjuvant chemotherapy in locally advanced gastric cancer with epirubicin, oxaliplatin, and capecitabine (EOX): A retrospective analysis. (2010) (0)
- COMMENT ON: VINORELBINE-INDUCED PANCREATITIS: A CASE REPORT (1998) (0)
- Multimodality approach for advanced esophageal carcinoma (1998) (0)
- Chemotherapie des Magenlymphoms (2002) (0)
- 722 Cbl-b silenced, autologous PBMCs as a novel anti-cancer therapy using the closed cell processing platform EPiC – a phase 1b trial with APN401 (2022) (0)
- Abstract LB187: Case report: APN401, a novel cancer therapy using Cbl-b silenced autologous PBMCs, induced stable disease in two patients with advanced solid tumors (2023) (0)
- 5. A new double-tracer methodology in the diagnosis of hepatocellular carcinoma: 99Tcm-galactosyl-neoglycoalbumin in combination with 123I-tyr-14-insulin (1994) (0)
- Corrigendum to ‘How I treat medullary thyroid cancer’ (2022) (0)
- Pulmonary neuroendocrine tumours and somatostatin receptor status: an assessment of unlicensed use of somatostatin analogues in the clinical practice (2022) (0)
- FIRST LINE SYSTEMIC TREATMENT IN MUCOSA‐ASSOCIATED LYMPHOID TISSUE (MALT) LYMPHOMA NOT ELIGIBLE FOR H. PYLORI ERADICATION – DO WE NEED CHEMOTHERAPY? (2019) (0)
- D-Verapamil and Adriamycin tn the treatment of advanced colorectal cancer (1994) (0)
- Contents Vol. 65, 2003 (2003) (0)
- Abstract 4777: Loss of death receptor 5 expression in plasmacytic MALT lymphoma is associated with genetic aberrations (2011) (0)
- Treatment patterns and oncological outcome of patients with advanced small intestinal neuroendocrine tumors: real-world data from the Medical University of Vienna (2022) (0)
- R andomized M ulticenter P hase I I T rial o f O xaliplatin P lus Irinotecan V ersus R altitrexed a s F irst-Line T reatment i n Advanced C olorectal C ancer (2002) (0)
- Impact of ABO Blood Group Type on Risk of Venous Thromboembolism in Patients with Cancer (2021) (0)
- Retraction Statement. Paper by Wang et al.: Oncology 2005;69:208-213 (DOI: 10.1159/000088332) (2015) (0)
- SMALL INTESTINE 18F - fluoro - deoxy - glucose positron emission tomography (18F - FDG - PET) for assessment of enteropathy - type T cell lymphoma (2003) (0)
- [Neuroendocrine tumors in daily gastroenterology and endoscopy - a practice manual]. (2019) (0)
- Subject Index Vol. 22, 1999 (1999) (0)
- Safety and efficacy of clarithromycin monotherapy in patients (pts) with extranodal marginal zone lymphoma (EMZL) (2016) (0)
- Subject Index Vol. 64, 2003 (2003) (0)
- Liposome-Encapsulated Doxorubicin Is Highly Active in Patients with B- as Well as T/NK-Cell Lymphomas and Cardiac Comorbidity or Older Age (2008) (0)
- New imaging method for the detection of gastric lymphomas (2021) (0)
- mantle cell lymphoma 435 APOPTOSIS-RELATED GENES IDENTIFY POOR SURVIVAL GROUP AMONG MANTLE CELL LYMPHOMA PATIENTS (2008) (0)
- Detection of extranodal lymphoma of mucosa-associated lymphoid tissue-type in the thyroid gland using combined x ray computed tomography/single-photon emission computed tomography technology: a case report. (2004) (0)
- 123I-Vascular Endothelial Growth Factor-165 (123I-VEGF165) Scintigraphyfor Visualisation of Extranodal Marginal Zone B-Cell Lymphoma of theMucosa-Associated Lymphoid Tissue (MALT) Type (2013) (0)
- This letter was referred to the author who responds as follows (1997) (0)
- Sections Vol. 65, 2002 (2002) (0)
- Band 22, Heft 4, August 1999 (1999) (0)
- Subject index for 1993 (1993) (0)
- [Helicobacter pylori, a risk factor for stomach cancer and primary stomach lymphoma?]. (1994) (0)
- Subject Index Vol. 60, 2001 (2001) (0)
- Plasma biomarker study of lenvatinib in gastroenteropancreatic neuroendocrine tumors reveals Ang2 and FGF2 as predictors of treatment response: Results from the international phase II TALENT trial (GETNE 1509). (2021) (0)
- Comparison With F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging (2016) (0)
- 3227 A phase II trial of ofatumumab for mucosa-associated lymphoid tissue lymphoma (MALT lymphoma) - An interim analysis (2015) (0)
- IELSG40/CLEO phase II trial of clarithromycin and lenalidomide in relapsed/refractory extranodal marginal zone lymphoma. (2022) (0)
- PRIMARY EXTRANODAL MARGINAL ZONE LYMPHOMA of the LUNG (BALT-LYMPHOMA): Results of a Retrospective Analysis on Behalf of IELSG (2010) (0)
- Chapter 7 – Hepatobiliary Cancer (2018) (0)
- Subject Index Vol. 65, 2003 (2003) (0)
- Prophylactic treatment with oral azithromycin in cancer patients during the COVID-19 pandemic (OnCoVID): a randomized, single-blinded, placebo-controlled phase 2 trial (2023) (0)
- Subject Index Vol. 69, 2005 (2006) (0)
- Mucosa-associated lymphoid tissue lymphoma: a perspective on current and future therapeutic strategies (2015) (0)
- Diffusion-Weighted MRI for Lymphoma Restaging—Response (2015) (0)
- Evaluation of in vivo targeting of andenocarcinomas with In-111-DTPA-B72.3-antibody under treatment with interferon gamma (1994) (0)
- Antiproliferative effects of lanreotide Autogel in patients with enteropancreatic neuroendocrine tumours: results of CLARINET, a large international phase 3 study (2014) (0)
- Treatment of advanced breast cancer with taxotere and vinorelbine (VLB) ± human granulocyte colony-stimulating factor (GCSF) (1999) (0)
- Contents Vol. 60, 2001 (2001) (0)
- Rituximab Plus Subcutaneous Cladribine in Patients with Extranodal Marginal Zone B-Cell Lymphoma of the Mucosa Associated Tissue (MALT-LYMPHOMA): A Phase II Study by the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie) (2012) (0)
- Localised Synovial Sarcoma in Adolescents and Young Adults Versus Adults - Is There a Difference in Outcome? (2022) (0)
- Randomized M ulticenter P hase I I T rial o f T wo D ifferent Schedules o f C apecitabine P lus O xaliplatin a s F irst-Line Treatment i n A dvanced C olorectal C ancer (2003) (0)
- Contents Vol. 65, 2002 (2002) (0)
- Phase I/II trial of dexverapamil (DEX), epirubicin (EPI) plus GM-CSF in advanced pancreatic cancer: 142 (1994) (0)
- MONDTI: Molecular characterisation platform for identifying actionable mutations in advanced or metastatic cancers (2016) (0)
- Does pantoprazole alleviate mouth dryness in patients with Sjögren's syndrome? (2001) (0)
- PROGRESSION‐FREE SURVIVAL FOLLOWING LENALIDOMIDE‐BASED TREATMENT IS SIGNIFICANTLY LONGER IN EXTRAGASTRIC THAN IN GASTRIC MARGINAL ZONE B‐CELL LYMPHOMA OF THE MUCOSA‐ASSOCIATED LYMPHOID TISSUE LYMPHOMA (MALT LYMPHOMA) (2017) (0)
- The circulating form of neprilysin is not a general biomarker for overall survival in treatment-naïve cancer patients (2019) (0)
- Chapter 4 – Gastroesophageal Cancer (2018) (0)
- Microspectrofluorimetric determination of P-gp-mediated cellular verapamil efflux using needle biopsy tumor specimens: 25 (1994) (0)
- Scintigraphy with 111In-DOTA-lanreotide (111In-Mauritius) in patients with lung tumours (1999) (0)
- Contents Vol. 69, 2005 (2006) (0)
- Treatment o f E xtranodal M arginal Z one B -Cell L ymphoma of M ucosa-Associate d L ymphoid T issue T ype W ith Cladribine: A P hase I I S tudy (2002) (0)
- Chapter 8 – Lymphoma (2018) (0)
- Contents Vol. 64, 2003 (2003) (0)
- relapsed/refractory mantle cell lymphoma Anti-tumor activity of rituximab plus thalidomide in patients with (2013) (0)
- Chromosomalimbalances inprimary andmetastatic pancreatic carcinomaasdetectedbyinterphase cytogenetics: basicfindings andclinical aspects (1998) (0)
- Abstracts – Fatigue and Cancer. International Symposium, Köln, 03.–04.09.1999 (1999) (0)
- Reinduction therapywiththesame cytostatic regimen inpatients withadvancedcolorectal cancer (1998) (0)
- The characteristics and clinical course of MALT lymphoma: A 10-year single center analysis (2007) (0)
- Real life data on Lanreotide Autogel in the treatment of patients with neuroendocrine tumors (NET) - an interim analysis from SOPRANo study (2016) (0)
- Contents Vol. 70, 2006 (2007) (0)
- TRANSFORMED MUCOSA‐ASSOCIATED LYMPHOID TISSUE LYMPHOMAS: A SINGLE INSTITUTION RETROSPECTIVE STUDY INCLUDING PCR‐BASED CLONALITY ANALYSIS (2019) (0)
- Antitumor Activity of Lanreotide Autogel 120 mg in Enteropancreatic Neuroendocrine Tumour (NET) Patients: The Clarinet Open-Label Extension Study (2015) (0)
- 1953P Gender and molecular aspects of targeted therapy recommendations for therapy refractory solid tumours: Data from the real-world precision medicine platform MONDTI (2020) (0)
- Predictive Value of Clonal Peripheral Blood γTCR Rearrangement in Patients with Peripheral T-Cell Lymphoma. (2006) (0)
- Subject Index Vol. 70, 2006 (2007) (0)
- Diagnostic value of PET/MR and DWI for the evaluation of malignant lymphoma: preliminary results on 17 patients. (2015) (0)
- 151 O - Association between helicobacter pylori infection and pancreatic cancer (1996) (0)
- Current therapeutic concepts in mucosa-associated lymphoid tissue (MALT) lymphoma (2014) (0)
- Value of peptide receptor imaging using indium-111-octreotide (OCT) and iodine-123 vasoactive intestinal peptide (VIP) in patients with carcinoid tumours: Vienna University experience 1993–1998 (1999) (0)
- Antitumor activity of lanreotide autogel (LAN) in enteropancreatic net patients: The CLARINET open-label extension (OLE) study (2015) (0)
- Genetic Heterogeneity in MALT Lymphoma. (2006) (0)
- Long-term safety/tolerability of lanreotide autogel/depot (LAN) treatment for metastatic intestinal and pancreatic neuroendocrine tumours (NETs): Final results of the CLARINET open-label extension (OLE) (2016) (0)
- Chapter 2 – Lung Cancer (2018) (0)
- Radiolabeled peptides in oncology (2000) (0)
- 16. 123I-Vasoactive intestinal peptide (VIP) receptor scanning for pancreatic cancer (1996) (0)
- UICC Symposium on Testicular Cancer Tübingen 19./20. März 1999 (1999) (0)
- It's poverty - not the pandemic: the impact of COVID-19 and socioeconomic status on psychological distress in cancer patients (2022) (0)
- A pilot study of confocal laser endomicrosopy for staging and follow-up of gastrointestinal MALT-lymphoma: interim analysis of 15 consecutive cases (2013) (0)
- Pancreatic neuroendocrine tumours – new therapeutic concepts (2012) (0)
- Sa1593 A Pilot Study of Confocal LASER Endomicrosopy for Staging and Follow-up of Gastrointestinal MALT-Lymphoma: Interim Analysis of 15 Consecutive Cases (2013) (0)
- Gender specific aspects in patients with mantle cell lymphoma undergoing rituximab-based therapy – what role does gender play? (2018) (0)
- 653 APN401, a novel EPiC-based anti-cancer cell therapy, case report: Cbl-b silenced, autologous PBMCs induced stable disease in an appendix carcinoma patient (2022) (0)
- Subject Index Vol. 65, 2002 (2002) (0)
- Essential news for clinical practice—thyroid cancer (2023) (0)
- New Echographic Criteria for Malt-lymphoma Compared to Other Lymphoproliferative Diseases of the Orbit by Standardized Echography (2009) (0)
- 1692P SARS-CoV-2 RNA testing in cancer patients treated at a Department of Medical Oncology in Vienna, Austria (2020) (0)
- Fatigue and quality of life (QoL) in cancer patients — relations between haematological parameters and subjective assessment (1999) (0)
- My burning issues in neuroendocrine tumours (NET) (2018) (0)
- A phase II study of the PI3K inhibitor copanlisib in combination with the anti-CD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: treatment rationale and protocol design of the COUP-1 trial (2021) (0)
- Allogeneic Hematopoietic Stem Cell Transplantation in Mantle Cell Lymphoma: A Retrospective Analysis of 7 Patients (2015) (0)
- Contents Vol. 66, 2004 (2004) (0)
- Subject Index Vol. 66, 2004 (2004) (0)
- Azithromycin Concentrations During Long-Term Regimen in Patients With MALT Lymphoma (2021) (0)
- The ESMO-Magnitude of Clinical Benefit Scale (MCBS) in rare tumor entities: A real life experience at the Medical University Vienna (2016) (0)
- 447 Extended Analysis for Cancer Treatment (EXACT): Interim analysis of a prospective precision medicine trial (2015) (0)
- 135 P - Phase I/II trial of epirubicin (EPI) and high dose tamoxifen (TAM) as a potential modulator of multidrug resistance in advanced hepatocellular carcinoma (HCC) (1996) (0)
- Corrigendum to "Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up": [Annals of Oncology 31 (2020) 17-29]. (2022) (0)
- Contents, Vol. 16, 1993 (1983) (0)
- Early progression of disease (POD24) as survival predictor in MALT lymphoma. (2019) (0)
- Progression-Free Survival in Patients with Bronchopulmonary Neuroendocrine Tumors Treated with Lanreotide or Placebo: Adjustment for Crossover Effects in Placebo Arm (2023) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Markus Raderer?
Markus Raderer is affiliated with the following schools:
